Portfolio News
Sofinnova Industrial Biotech
Bon Vivant achieves self-affirmed GRAS status, notifying the FDA of its recombinant whey protein enabling commercialization in the U.S.
Lyon, France – 09 January 2025 – Bon Vivant, a global leader in precision fermentation technology, announces that its recombinant Beta-Lactoglobulin (BLG) whey protein, designed for use in hybrid and animal-free dairy products, has achieved self-determined Generally Recognized as Safe (GRAS) status and has notified the FDA of the GRAS conclusion.
Bon Vivant is the first precision fermentation company to present recombinant BLG in two distinct forms, offering tailored and superior techno-functional properties while maintaining the nutritional benefits of conventional dairy proteins.
“Securing the self-affirmed GRAS status is a testament to our commitment to safety, quality, and innovation,” said Stéphane Mac Millan, Bon Vivant’s CEO & co-founder. “Notifying the FDA of this GRAS conclusion not only reinforces our engagement with U.S. regulatory authorities but also positions Bon Vivant to meet the growing demand for sustainable, functional, high-performance dairy proteins.”
With self-affirmed GRAS status, Bon Vivant is now ready to commercialize its recombinant BLG in the U.S., while waiting for a No Questions Letter from the FDA (expected in 2025), further bolstering client and consumer confidence.
Sustainability at the core
Bon Vivant’s precision fermentation technology produces high-quality, functional dairy proteins with a significantly reduced environmental footprint. As demonstrated in Bon Vivant’s peer-reviewed Life Cycle Assessment (LCA), this innovation achieves:
● 72% reduction in greenhouse gas emissions;
● 81% reduction in water consumption;
● 99% reduction in arable land use compared to conventional dairy production.
By complementing conventional dairy farming, Bon Vivant addresses critical challenges posed by population growth and resource limitations, paving the way for a more sustainable and resilient food system.
For more information, visit bonvivant-food.com/en.
Related News
Bioptimus hits $76M funding milestone and prepares to launch groundbreaking foundation model for biology
Mediar Therapeutics enters into global licensing agreement with Lilly to advance first-in-class WISP1 antibody for the treatment of idiopathic pulmonary fibrosis (IPF)
Global debut in an ASC setting at Surgeon's Point Surgery Center for Moon Surgical's Maestro System
Tenpoint Therapeutics announces positive topline data from Phase 3 pivotal study, BRIO-II, of BRIMOCHOL™ PF for the treatment of presbyopia
Noema Pharma Appoints Michael Samar as Chief Financial Officer